Tumor-targeted gene therapy for nasopharyngeal carcinoma

Cancer Research

Volumn 62, Issue 1, 2002, Pages 171-178

  Li, Jian Hua ^a,e   Chia, Marie ^a,e   Shi, Wei ^a,e   Ngo, D ^a   Strathdee, Craig A ^f,g   Huang, Dolly ^e   Klamut, Henry ^a,e   Liu, Fei Fei ^a,b,e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NONE

^f ROBARTS RESEARCH INSTITUTE   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 BROMO 4 CHLORO 3 INDOLYL BETA DEXTRO GALACTOPYRANOSIDE; AD5ORIP.BETA GALACTOSIDASE; AD5ORIP.LUCIFERASE; AD5ORIP.P53; ADENOVIRUS VECTOR; DYE; GENE PRODUCT; PROTEIN EBNA1; PROTEIN ORIP; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; DNA REPLICATION ORIGIN; DOWNSTREAM PROCESSING; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE SEQUENCE; GENE THERAPY; HUMAN; HUMAN CELL; IONIZING RADIATION; LATENT PERIOD; LIVER; MULTIGENE FAMILY; NASOPHARYNX CARCINOMA; NUCLEOTIDE REPEAT; PRIORITY JOURNAL; REPORTER GENE; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BETA-GALACTOSIDASE; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; HUMANS; MICE; MICE, SCID; NASOPHARYNGEAL NEOPLASMS; REPLICATION ORIGIN; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036144266     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines
2. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma
3. The efficacy of ionizing radiation combined with adenoviral-mediated p53 therapy in EBV-positive nasopharyngeal carcinoma
4. Adenoviral p53 gene therapy promotes heat-induced apoptosis in a nasopharyngeal carcinoma cell line
5. Cisplatin chemotherapy plus adenoviral p53 gene therapy in EBV-positive and negative nasopharyngeal carcinoma
6. Epstein-Barr virus strain variation in nasopharyngeal carcinoma from the endemic and non-endemic regions of China
7. Epstein-Barr virus: The first human tumor virus and its role in cancer
8. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma
9. Epstein-Barr virusits replication
10. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma
11. Epstein-Barr virus. Biology, pathogenesis, and medical aspects
12. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA
13. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance
14. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection
15. Epstein-Barr virus-driven gene therapy for EBV-related lymphomas
16. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia
17. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus
18. Cytogenetic studies on an epithelial cell line derived from poorly differentiated nasopharyngeal carcinoma
19. Characterization of a newly derived human sarcoma cell line (HT-1080)
20. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region
21. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells
22. Transactivation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1
23. Isolation of human sequences that replicate autonomously in human cells
24. Synergistic interactions between overlapping binding sites for the serum response factor and ELK-1 proteins mediate both basal enhancement and phorbol ester responsiveness of primate cytomegalovirus major immediate-early promoters in monocyte and T-lymphocyte cell types
25. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
26. Adenovirus-p53 gene therapy in human nasopharyngeal carcinoma xenografts
27. Nasopharyngeal carcinoma: Classification and histological appearances
28. Detection of Epstein-Barr virus DNA in well and poorly differentiated nasopharyngeal carcinoma cell lines
29. The human cytomegalovirus major immediate-early distal enhancer region is required for efficient viral replication and immediate-early gene expression
30. Characterization of the sequences of the human cytomegalovirus enhancer that mediate differential regulation by natural and synthetic retinoids
31. The transcription factor YYI binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in non-permissive cells
32. Gfi-1 encodes a nuclear zinc finger protein that binds DNA and functions as a transcriptional repressor
33. Gene therapy: Designer promoters for turnout targeting
34. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter
35. Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53
36. P53 tumor suppressor gene therapy for cancer
37. Combined radiation and p53 gene therapy of malignant glioma cells
38. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
39. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity
40. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death
41. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells
42. Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis
43. Gene replacement strategies for treating non-small cell lung cancer
44. Replicative adenoviruses for cancer therapy
45. Epstein-Barr virus infection
46. Interaction of human adenovirus serotype 2 with human lymphoid cells
47. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5
48. 5 promote adenovirus internalization but not virus attachment